In previous work, we demonstrated that a dose of 500 μM of ICG, without premixing with human serum albumin, was optimal to perform NIR fluorescence SLN mapping in breast cancer.18,19 In the current randomized clinical trial, the added value of patent blue staining, when used in combination with NIR fluorescence, was assessed in breast cancer patients undergoing the SLN procedure. The gene discussed is ALB; the disease is breast carcinoma.